NCT05116761View on ClinicalTrials.gov

ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Covid19Postviral SyndromeDyspnea
Interventions
BIOLOGICAL

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles

Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles

OTHER

Saline

Placebo Saline

Sponsors
All Listed Sponsors
lead

Direct Biologics, LLC

INDUSTRY